Literature DB >> 14726170

Malaria vaccine developments.

Vasee S Moorthy1, Michael F Good, Adrian V S Hill.   

Abstract

Large gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades. Malaria now kills 2-3 million people yearly. Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed. Advances in vaccine technology and immunology are being used to develop malaria subunit vaccines. Novel approaches that might yield effective vaccines for other diseases are being evaluated first in malaria. We describe progress in malaria vaccine development in the past 5 years: reasons for cautious optimism, the type of vaccine that might realistically be expected, and how the process could be hastened. Although exact predictions are not possible, if sufficient funding were mobilised, a deployable, effective malaria vaccine is a realistic medium-term to long-term goal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726170     DOI: 10.1016/S0140-6736(03)15267-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

1.  Liver stage antigen and malaria.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-08-06       Impact factor: 4.599

2.  Malaria update.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

Review 3.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

4.  Naturally acquired IgG antibodies against the C-terminal part of Plasmodium falciparum sporozoite threonine-asparagine-rich protein in a low endemic area.

Authors:  Chittakun Suwancharoen; Chaturong Putaporntip; Thanaporn Rungruang; Somchai Jongwutiwes
Journal:  Parasitol Res       Date:  2011-02-01       Impact factor: 2.289

5.  Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.

Authors:  Margaret Pinder; Colin J Sutherland; Fatoumatta Sisay-Joof; Jamila Ismaili; Matthew B B McCall; Rosalyn Ord; Rachel Hallett; Anthony A Holder; Paul Milligan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 6.  Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one?

Authors:  Bruno Douradinha; Maria M Mota; Adrian J F Luty; Robert W Sauerwein
Journal:  Infect Immun       Date:  2007-12-03       Impact factor: 3.441

Review 7.  Towards an effective malaria vaccine.

Authors:  Pedro Aide; Quique Bassat; Pedro L Alonso
Journal:  Arch Dis Child       Date:  2007-06       Impact factor: 3.791

Review 8.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 9.  How might infant and paediatric immune responses influence malaria vaccine efficacy?

Authors:  A M Moormann
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

10.  Generation, annotation, and analysis of ESTs from midgut tissue of adult female Anopheles stephensi mosquitoes.

Authors:  Deepak P Patil; Santosh Atanur; Dhiraj P Dhotre; D Anantharam; Vineet S Mahajan; Sandeep A Walujkar; Rakesh K Chandode; Girish J Kulkarni; Pankaj S Ghate; Abhishek Srivastav; Kannayakanahalli M Dayananda; Neha Gupta; Bhakti Bhagwat; Rajendra R Joshi; Devendra T Mourya; Milind S Patole; Yogesh S Shouche
Journal:  BMC Genomics       Date:  2009-08-20       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.